Tag Archives: JOBS Act

As mentioned in Fierce Biotech, a new crop of biotech IPO hopefuls have recently thrown their hats into the ring. These three biotechs are targeting $175M in IPO cash, hoping to secure funding for oncology, pain, and rare diseases. In fact, there have been 96 IPOs since the passage of the JOBS Act in April of 2012. One important provision of the Act is the ability for emerging growth companies to conduct “testing the waters” meetings with Read More >

Investors are increasingly interested in biotechnology based on scientific breakthroughs, an improved regulatory environment, strong earnings growth from large companies, and a more mature industry. Recent advancements in biotechnology are revolutionizing treatments and cures for many illnesses, creating new value for the healthcare system. In 2013, our understanding of how therapeutics can be used to harness the immune system to destroy cancer cells exploded with many companies reporting solid data in human testing. In 2014, Read More >

Because small biotechnology companies do not have product revenue, burdensome regulations have an outsized effect on them. One-size-fits-all compliance requirements – such as Section 404(b) of the Sarbanes-Oxley Act (SOX) – divert funds from the lab and slow the development process. We have already seen the benefits that positive legislative reform can have for capital formation for emerging growth companies (EGCs). The JOBS Act has led to a sea change in the regulatory landscape and Read More >

Passed in 2012, the Jumpstart Our Business Startups (JOBS) Act makes the pathway to capital formation more attainable for small biotechnology companies, clearing the way for American innovation and ingenuity by removing bureaucratic hurdles and red tape to speed cures and medical breakthroughs to patients. In this short video, leading BIO Board Members and biotech company CEOs share the reasons why they feel the JOBS Act is critically important for today’s biotech industry. The JOBS Read More >

Today, the San Francisco Business Times published an op-ed by OncoMed President and CEO Paul Hastings lauding the Jumpstart Our Business Startups Act (JOBS) Act for giving emerging biotech companies a much-needed boost. As Hastings points out, 80-plus companies will have gone public in the last two years with the help of the JOBS Act. As the biotech industry gathers in San Diego next month for the 2014 BIO International Convention, several CEOs in attendance will no Read More >